The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.
about
The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban settingManagement of Hepatitis C Post-liver Transplantation: a Comprehensive ReviewAntiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus InfectionInjecting drug use: A vector for the introduction of new hepatitis C virus genotypesHepatitis C cirrhosis: New perspectives for diagnosis and treatmentEmerging therapies for hepatitis CHepatitis C virus: A global viewEconomic evaluation of screening programs for hepatitis C virus infection: evidence from literatureModeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infectionsHepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion.AACR Cancer Progress Report 2014Hepatitis C Virus E2 Envelope Glycoprotein Core StructureBest strategies for global HCV eradication.Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United StatesTrends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007Seroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testingPrevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of NepalAgent-Based Model Forecasts Aging of the Population of People Who Inject Drugs in Metropolitan Chicago and Changing Prevalence of Hepatitis C InfectionsModeling the Health and Economic Burden of Hepatitis C Virus in SwitzerlandRisk of end stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort.Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death.Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.Global epidemiology and burden of HCV infection and HCV-related disease.Reinventing HCV Treatment: Past and Future Perspectives.Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugsCapitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designUnderestimation of liver-related mortality in the United States.Estimating the prevalence of hepatitis C infection in New York City using surveillance dataAnnual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.HCV screening in a cohort of HIV infected and uninfected homeless and marginally housed women in San Francisco, CaliforniaFollow-up testing for hepatitis C virus infection: an analysis of Massachusetts surveillance data, 2007-2010.Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs.All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C.Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C.Identifying and characterizing hepatitis C virus hotspots in Massachusetts: a spatial epidemiological approach.Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study.Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era.Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis.
P2860
Q21559628-8C0CB339-0111-48B6-BB75-D7669DB80514Q26781741-3135F212-7687-4B25-95E3-21D680FF4557Q26781962-CC11435D-00D0-4ACE-B33D-3095C1E87345Q26781991-687F80F5-2F80-4D1E-ADE6-F8B547D8ABA6Q26799924-7921D5F2-4438-49E4-A850-FB2B70964771Q26853642-0A4E1FC7-A1AD-494B-A448-758C2DCEFB44Q26862531-35F5C7B5-6100-47CE-A1FB-907F53828961Q26998567-9D86A2F2-9834-4806-AA9A-11A90819D20AQ27002381-9449E847-D700-4BEC-9A05-84BB88601D40Q27321791-F3905F1B-FCA9-4A1B-9CF4-E1C924CA8A07Q27346723-BDD7EB02-B2E5-4E75-B006-0C921EC651C6Q27680704-FF126C46-6FBB-449C-9D6A-CC3415FBF5F7Q27693824-ABAEC18A-3E28-456B-A5C3-873EB468E50FQ28488762-242C7297-36BE-4C2B-B69D-D6EB3D330185Q28533642-23FF6BCE-9EA9-4A29-9B75-13BB937B9AEFQ28545237-42C5F978-47FF-4D46-A6B8-66E0693CF31EQ28547151-0D6283FD-49A2-41A1-A93B-74D1E74F05DBQ28548643-FB5EDB05-11E3-431A-94D6-B2E9D36DD3EAQ28548657-F31970EA-3506-40DD-9609-37B9FA05146DQ30151351-ADD2120A-6CDA-4CAA-94E7-3FD548F21345Q30151690-17FC2016-8F3F-4A47-AE48-B084AABAE47FQ30209037-76BA266B-6AFC-4864-BE5C-1DA159E5FD37Q30240220-16A824C1-BD62-4777-BDB9-7AC4DC575358Q30241881-83ABE4BB-4488-4D4B-8B1A-B56BC7402277Q30364309-2EC81E1D-AA6E-4FE6-A1F5-D1D912EEF422Q30369227-58BDF0D0-101E-4765-805A-6AD3B6FB2B14Q30374314-988495CF-5FD7-4CA4-9B95-D1A4502696ACQ30564165-E871A906-CD04-4618-8919-DF07C51DE574Q30622845-8A21847E-E16D-4C3E-BB6A-9B9CA1F1D7DFQ30746254-402D9664-53CB-4E7D-A36A-20907F03BD71Q30837913-C24D3F56-5CDA-4195-8C49-D9E5A865111CQ30846888-6150F495-14B1-433C-BA92-A69F59F3D062Q31168171-8279C274-5381-4BB7-8F3B-187CE44ED121Q33413353-C8F674A0-ABFA-4822-9E4F-86B4AD7D7D1DQ33424681-EEBDCF3E-73A8-4842-B92E-42D24074B001Q33587555-1F93A70E-C3D3-4052-846A-51D5E1FD2B15Q33629380-5978827A-1354-42F4-A785-8B42B9907942Q33629538-78C39425-035E-4AD5-9E0E-B5F1CE0F211CQ33696050-807399E3-DCC0-45D5-B1E9-979489816B0BQ33702754-BEC40188-CE56-4D0A-B424-BDEBCD0AC876
P2860
The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
The increasing burden of morta ...... States between 1999 and 2007.
@en
The increasing burden of morta ...... States between 1999 and 2007.
@nl
type
label
The increasing burden of morta ...... States between 1999 and 2007.
@en
The increasing burden of morta ...... States between 1999 and 2007.
@nl
prefLabel
The increasing burden of morta ...... States between 1999 and 2007.
@en
The increasing burden of morta ...... States between 1999 and 2007.
@nl
P2093
P1476
The increasing burden of morta ...... States between 1999 and 2007.
@en
P2093
John W Ward
Kathleen N Ly
R Monina Klevens
Ruth B Jiles
Scott D Holmberg
P304
P356
10.7326/0003-4819-156-4-201202210-00004
P407
P577
2012-02-01T00:00:00Z